|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
SCIDIR_on1151516993 |
| 003 |
OCoLC |
| 005 |
20231120010448.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
200421s2020 xx o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e rda
|e pn
|c YDX
|d OPELS
|d EBLCP
|d OHS
|d OCLCO
|d OCLCF
|d OCLCQ
|d OCLCO
|d GZM
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 019 |
|
|
|a 1151729740
|
| 020 |
|
|
|a 9780128168479
|q (electronic bk.)
|
| 020 |
|
|
|a 0128168471
|q (electronic bk.)
|
| 020 |
|
|
|z 0128168463
|
| 020 |
|
|
|z 9780128168462
|
| 035 |
|
|
|a (OCoLC)1151516993
|z (OCoLC)1151729740
|
| 050 |
|
4 |
|a QP551.5
|
| 082 |
0 |
4 |
|a 572/.6
|2 23
|
| 245 |
0 |
0 |
|a Protein interactions as targets in drug discovery /
|c edited by Rossen Donev.
|
| 264 |
|
1 |
|a [Place of publication not identified] :
|b Academic Press,
|c 2020.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Advances in protein chemistry and structural biology ;
|v v. 121
|
| 505 |
0 |
|
|a Front Cover -- Advances in Protein Chemistry and Structural Biology -- Protein Interactions as Targets in Drug Discovery -- Copyright -- Contents -- Contributors -- One -- Latest trends in structure based drug design with protein targets -- 1. Introduction -- 2. Basics of thermodynamics -- 3. Forces responsible for protein-ligand interactions -- 4. Receptors of their characteristics -- 5. Physico-chemical principles of protein-ligand binding -- 6. Thermodynamic models of receptor-protein-ligand bindings -- 7. Computational techniques in structure based drug discovery -- 8. Final words
|
| 505 |
8 |
|
|a Acknowledgments -- References -- Two -- Computational approaches for identifying potential inhibitors on targeting protein interactions in drug discovery -- 1. Introduction -- 2. Protein-ligand and protein-protein interactions in diseases -- 2.1 Targeting protein-ligand interactions -- 2.2 Druggable proteome -- 2.3 Protein-protein interactions: expanding the druggable proteome -- 3. Computational approaches -- 3.1 Structure based drug design -- 3.2 Virtual screening -- 3.3 Fragment based drug design -- 3.3.1 Fragment growing -- 3.3.2 Fragment linking -- 3.4 Modeling and docking
|
| 505 |
8 |
|
|a 3.5 Molecular dynamics simulations -- 3.6 Quantitative structure activity relationship -- 3.7 Proteochemometric and polypharmacological modeling -- 4. Applications -- 4.1 Mimicking Bcl-2 PPIs in cancer -- 4.1.1 QSAR models -- 4.1.2 Scaffold hopping -- 4.2 Inhibitors for RNA polymerase in dengue -- 4.2.1 Fragment based drug design -- 4.2.2 Quercetin derivatives as potential inhibitors -- 4.2.3 Flavonoids as potential inhibitors -- 4.3 Inhibitors for cYes kinase in cancer -- 4.3.1 Structure based virtual screening -- 4.3.2 Structure based (SB) and pharmacophore based (PB) tandem screening
|
| 505 |
8 |
|
|a 4.3.3 Contest based approach for identifying potential inhibitors of cYes kinase -- 4.4 Mutation specific inhibitors for EGFR in cancer -- 5. Conclusions -- Acknowledgments -- References -- Three -- Role of protein-protein interactions in allosteric drug design for DNA methyltransferases -- 1. Introduction -- 2. DNMT family structures -- 2.1 Domain structures and protein-protein interactions of DNMT1 and DNMT3A -- 2.2 Allosteric regulations of DNMT1 and DNMT3A involved in the protein-protein interactions -- 3. Theory and methodology -- 3.1 PSN and MD
|
| 505 |
8 |
|
|a 3.2 Normal mode analysis of elastic network model -- 3.3 Perturbation response scanning approach -- 3.4 Sequence co-evolution -- 3.5 Identification of allosteric pockets -- 4. DNMT1 -- 4.1 ANM applications -- 4.2 GNM applications -- 4.3 PRS calculations -- 4.4 PSN with MD simulations -- 4.5 Coevolutionary analysis -- 4.6 Potential allosteric pockets -- 5. DNMT3A -- 5.1 ANM applications -- 5.2 GNM applications -- 5.3 PSN applications -- 5.4 Coevolutionary analysis -- 5.5 Allosteric paths -- 5.6 Potential allosteric pockets -- 6. Concluding remarks -- Acknowledgments -- References
|
| 505 |
8 |
|
|a Four -- Physicochemical determinants of antibody-protein interactions
|
| 650 |
|
0 |
|a Protein-protein interactions.
|
| 650 |
|
0 |
|a Drugs
|x Design.
|
| 650 |
|
2 |
|a Protein Interaction Maps
|0 (DNLM)D060066
|
| 650 |
|
2 |
|a Drug Discovery
|0 (DNLM)D055808
|
| 650 |
|
2 |
|a Drug Design
|0 (DNLM)D015195
|
| 650 |
|
6 |
|a Interactions prot�eine-prot�eine.
|0 (CaQQLa)201-0396409
|
| 650 |
|
6 |
|a M�edicaments
|x Conception.
|0 (CaQQLa)201-0203461
|
| 650 |
|
7 |
|a Drugs
|x Design
|2 fast
|0 (OCoLC)fst00898790
|
| 650 |
|
7 |
|a Protein-protein interactions
|2 fast
|0 (OCoLC)fst01079705
|
| 700 |
1 |
|
|a Donev, Rossen.
|
| 776 |
0 |
8 |
|i Print version:
|t Protein interactions as targets in drug discovery.
|d [Place of publication not identified] : Academic Press, 2020
|z 0128168463
|z 9780128168462
|w (OCoLC)1122910008
|
| 830 |
|
0 |
|a Advances in protein chemistry and structural biology ;
|v v. 121.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/18761623/121
|z Texto completo
|
